Janssen-Cilag
BEERSE, Belgium, June 15, 2010 - Janssen-Cilag today welcomes the approval by the European Commission of
the update to the Summary of Product Characteristics (SmPC) for Velcade(R)
(bortezomib) for the treatment of patients with multiple myeloma.
BEERSE, Belgium, June 15, 2010 - Janssen-Cilag today welcomes the approval by the European Commission of
the update to the Summary of Product Characteristics (SmPC) for Velcade(R)
(bortezomib) for the treatment of patients with multiple myeloma.
HIGH WYCOMBE, England, May 19, 2010 - New research published online in the Journal of the American
Academy of Dermatology (JAAD) shows that treatment with STELARA(TM)(Black
Triangle Drug) (ustekinumab) significantly improves symptoms of depression,
anxiety and health-related quality of life in patients with moderate to
severe psoriasis compared to placebo.
HIGH WYCOMBE, England, February 8 - STELARA (ustekinumab) has today been accepted by the Scottish Medicines
Consortium (SMC) for restricted use within NHS Scotland for the treatment of
moderate to severe plaque psoriasis.(1) STELARA is the first in a novel class
of biologics.
HIGH WYCOMBE, England, January 14 - For Medical Media Only
- Results From First Phase III Comparator Study of Biologic
Agents in Psoriasis Published Today in New England Journal of Medicine
Findings from a new Phase III study comparing the efficacy and safety of
STELARA(TM)(ustekinumab) with etanercept in the treatment of moderate to
severe plaque psoriasis, show a significantly higher clinical response with
STELARA over a 12-week period compared to high-dose etanercept (50mg
twice-weekly).